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Abstract
Background: The chemokine CCL5 is involved in the recruitment of immune cells and a subsequent activation of hepatic
stellate cells (HSC) after liver injury. We here investigate whether inhibition of CCL5 oligomerization and glycosaminoglycan
binding by a mutated CCL5 protein (
44AANA
47-CCL5) has the potential to ameliorate liver cell injury and fibrosis in vivo.
Methodology: Liver injury was induced in C57BL/6 mice by intraperitoneal injection of carbon tetrachloride (CCl4)i na n
acute and a chronic liver injury model. Simultaneously, mice received either
44AANA
47-CCL5 or vehicle. Liver cell necrosis
and fibrosis was analyzed by histology, and measurement of serum transaminases and hydroxyproline. Intrahepatic mRNA
expression of fibrosis and inflammation related genes were determined by quantitative RT-PCR and infiltration of immune
cells was assessed by FACS analysis and immunocytochemistry. In vitro, HSC were stimulated with conditioned media of T-
cell enriched splenocytes.
Principal Findings:
44AANA
47-CCL5 treated mice displayed a significantly reduced degree of acute liver injury (liver cell
necrosis, transaminases) and fibrosis (Sirus red positive area and hydroxyproline content) compared to vehicle treated mice.
Ameliorated fibrosis by
44AANA
47-CCL5 was associated with a decreased expression of fibrosis related genes, decreased a-
smoth muscle antigen (aSMA) and a reduction of infiltrating immune cells. In the acute model,
44AANA
47-CCL5 treated mice
displayed a reduced immune cell infiltration and mRNA levels of TNF, IL-1 and CCL3 compared to vehicle treated mice. In
vitro, conditioned medium of T-cell enriched splenocytes of
44AANA
47-CCL5 treated mice inhibited the chemotaxis and
proliferation of HSC.
Conclusions: The results provide evidence that inhibition of oligomerization and glycosaminoglycan binding of the
chemokine CCL5 is a new therapeutic strategy for the treatment of acute and chronic liver injuries and represents an
alternative to chemokine receptor antagonism.
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Introduction
Acute and chronic liver diseases are a major cause of morbidity
and mortality worldwide. In most diseases an inflammatory
response within the liver is a mainstay of tissue damage [1]. After
acute injury, an overwhelming immune response can lead to
massive hepatocyte damage and subsequent liver failure [2]. On
the other hand a continuous, low-level inflammation is a central
pathophysiological aspect of liver fibrogenesis which ultimately
leads to the development of liver cirrhosis in a significant number
of cases [3]. Therefore, elucidation of pivotal inflammatory
pathways in liver disease models might of great clinical interest
as interference with these pathways bears the potential for new
therapeutic options in diverse acute and chronic liver diseases.
The inflammatory infiltrate within the damaged liver consists of
different immune cells subsets, including macrophages, dendritic
cells, T cells, NK cells, NKT-cells and B-cells. Most of these cells
are recruited into the liver along a chemotactic gradient. Classical
chemoattractant molecules are chemokines, which are long known
to govern the directed migration of leukocytes to sites of
inflammation. In recent years, an important role of chemokines
has also been deciphered in liver diseases [4]. Chemokines bind
with high affinity to classical G-protein coupled receptors on the
cell membrane of target cells and with lower affinity to
glycosaminoglycans (GAG) of the extracellular matrix and
endothelial cell surfaces [5]. Interaction of chemokines with
GAG appears to be essential for the in vivo activity of certain
chemokines and is considered as a prerequisite for establishing
a chemotactic gradient across endothelial barriers [6]. Another
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36614biochemical characteristic of chemokines is their ability to form
higher order oligomers what appears to be essential for their GAG
binding and chemotactic activity in vivo [7].
CCL5 (traditional name: regulated upon activation, normally T
cell expressed and secreted, RANTES) belongs to the CC family of
inflammatory chemokines and is expressed by many liver resident
and infiltrating cells [8]. In humans, CCL5 expression is up-
regulated in acute and chronic liver damage [9,10,11] and
functional Ccl5 gene variants have been associated with inflamma-
tory liver damage [12,13] and treatment response [14]. Notably, in
murine models of experimental fibrosis, CCL5 and its receptors
CCR1 and CCR5 have been shown to be essential for fibrosis
progression[9,15].Furthermore,antagonismoftheCCL5receptors
with Met-CCL5 ameliorated liver fibrosis and accelerated the
regression of scar formation in vivo [9]. Thus, this particular
chemokine might be an attractive candidate for anti-inflammatory
or anti-fibrotic therapies of liver diseases. However, chemokine
receptor antagonism bears the potential for numerous unwanted
side effects [16]. Therefore, other therapeutic strategies of
chemokine antagonism should be systematically investigated.
Based on this background, we here investigate a novel
therapeutic approach to interfere with the chemokine CCL5 in
experimental liver damage models. We show that administration
of the CCL5 mutant
44[AANA]
47-CCL5, which loses the ability to
oligomerise, but forms inactive heterodimers with wild-type CCL5
Figure 1. In vivo effects of treatment with [
44AANA
47]-CCL5 on acute liver cell injury. (A) Mice treated with [
44AANA
47]-CCL5 have reduced
serum transaminases 48 hours after CCl4 application compared to vehicle treated mice. (B) Reduced liver cell damage is also evidenced by reduced
necrotic areas 48 h hours after injury (HE staining, 6100). (C) The ameliorated damage after 48 h in [
44AANA
47]-CCL5 treated mice is preceded by
a significantly reduced infiltration of CD45+ immune cells. (D) Reduced inflammatory liver damage in [
44AANA
47]-CCL5 is also associated with
significantly repressed pro-inflammatory mRNA expression (black bars: [
44AANA
47]-CCL5, open bars: vehicle). * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0036614.g001
CCL5 Antagonism in Liver Disease
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36614and loses 80% of its capacity to bind to GAG [17], strongly
reduces acute liver injury and tissue fibrosis in vivo.
Materials and Methods
Murine in vivo experiments
Male wild-type (WT) mice on the C57BL/6 background
(purchased from Charles River Laboratories) were subjected at
the age of 8 weeks to two different liver damage models. In the first
model, WT mice received a single intraperitoneal (i.p.) injection of
carbon tetrachloride (CCl4, 0.8 mg/kg bodyweight) to induce
acute liver injury. Animals were treated with the CCL5 antagonist
[
44AANA
47]-CCL5 [17] or vehicle (PBS) i.p. before as well as 12
and 24 hours after liver damage. Mice were sacrificed 24 or
48 hours (n=6/group) after the CCl4 administration for further
analysis. In the second model, mice received repeated i.p.
injections CCl4 for 6 weeks (0.6 mg/kg bodyweight in 1:1 mineral
oil, twice weekly) to induce liver fibrosis. Mice were sacrificed
three days after the last CCl4 injection when the peek of fibrosis is
expected [9]. [
44AANA
47]-CCL5 (10 mg daily) or vehicle (PBS,
Figure 2. In vivo effects of treatment with [
44AANA
47]-CCL5 on chronic liver injury. (A) Treatment of mice with [
44AANA
47]-CCL5 in parallel
to chronic CCl4 intoxication reduced scar formation in the liver compared to vehicle (representative Sirius red stainings, 6100). Ameliorated liver
fibrosis in [
44AANA
47]-CCL5 treated mice is quantified by a reduced Sirius red positive area (B) and a decreased hepatic concentration of the collagen
specific amino acid hydroxyproline (C). ALT levels were not significantly changed in [
44AANA
47]-CCL5 treated mice compared to vehicle treated mice
when taken 72 h after the last CCl4 injection (D). ** P,0.01.
doi:10.1371/journal.pone.0036614.g002
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mice, serum samples were obtained via cardiac puncture and livers
were harvested for histological and biochemical analysis.
All animals were housed under specific-pathogen-free condi-
tions in the animal facility of the RWTH University hospital
Aachen. The experiments were carried out after approval by the
animal welfare board at the Bezirksregierung Cologne, Germany
(permit number 50.203.2-AC 5a, 51/06).
Histological and biochemical evaluation of liver damage
Liver fibrosis was assessed histologically by quantification of the
Sirius-red positive area on 10 low power (406) fields/slide by use of
the NIH software Image J, which is available from http://rsbweb.
nih.gov/. Hepatic collagen content was analyzed biochemically by
photometric measurement of the collagen specific amino acid
hydroxyproline as recently described [9]. The intrahepatic expres-
sionofa-smoothmuscleantigen(a-SMA)wasassessedhistologically
with a mouse anti-SMA (Clone1A4, Dako) antibody. Immunohis-
tochemical stainings for immune cell infiltration were performed in
cooperation with the Institute of Pathology of University Hospital
Bonn, Germany. The following antibodies were used: CD45, rat
Clone30-F11 (BD Sciences); CD3, rabbit Clone SP7 (LabVision);
F4/80, rat Clone BM8 (Dianova).
Hepatic immune cell isolation and flow cytometry
analysis
Single-cell suspensions were isolated from freshly harvested
livers using mechanical and enzymatic digestion. Viable white
blood cells were purified from the suspension by centrifugation for
20 min at 8006 g with a density gradient separation medium
(Lymphocyte, PAA Laboratories). PBMCs were collected from the
gradient/supernatant interface and then washed in Hank’s
balanced salt solution (PAA Laboratories) supplemented with 1%
bovine serum albumin and 2 mM ethylene diamine tetraacetic
acid (EDTA). For flow cytometry analysis, cells were stained with
fluorochrome-conjugated antibodies for CD3, CD4, CD8, CD45
and NK1.1 (all antibodies from Bioscience) and the relative
numbers were quantified using the FACSCanto II (Becton
Dickinson). Data were analyzed using FlowJo software (Tree Star).
a-SMA Western blot
Snap-frozen liver samples were homogenised in 1 ml RIPA
buffer (20 mM Tris-HCl, 150 mM NaCl, 2% Nonidet P40, 0.1%
SDS, 0.5% Na-deoxycholate) with proteinase inhibitor (Mini
Complete Protease Inhibitor Cocktail Tablets, Roche Applied
Figure 3. Treatment with [
44AANA
47]-CCL5 is associated with
reduced stellate cell activation. (A) Mice treated with [
44AANA
47]-
CCL5 concomitantly to CCl4 display repressed mRNA expressions of the
pivotal stellate cell genes Col1a1 and Timp1 compared to vehicle
treated animals, while the mRNA of Tgf-b showed only a trend to lower
expression. (B) Reduced activation of stellate cells in [
44AANA
47]-CCL5
treated mice is further evidenced by decreased protein expression of
the stellate cell activation marker aSMA by immunohistochemistry
(upper panels) and western bot of total liver extracts (lower panel). *
P,0.05.
doi:10.1371/journal.pone.0036614.g003
Figure 4. Treatment with [
44AANA
47]-CCL5 leads to altered
immune cell infiltration during liver fibrogenesis. The photo-
micrographs show representative liver sections of mice treated with
[
44AANA
47]-CCL5 or vehicle after staining for CD45 (total leukocytes),
CD3 (T-cells) and macrophages (F4/80). Magnification 6100.
doi:10.1371/journal.pone.0036614.g004
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was performed from total liver protein, using a monoclonal mouse
anti-mouse a-SMA antibody (Millipore). The primary antibody
was visualized using horseradish peroxidase–conjugated anti-
mouse IgG (DAKO) and the PIERCE ECL Western Blotting
Substrate (Thermo Scientific). b-actin was used as loading control.
mRNA expression analysis of murine fibrogenic and
inflammatory genes
Total RNA was isolated from livers with peqGold TriFast
(Peqlab) and reversely transcribed using RevertAid Premium FS
cDNA Synthesis Kit (Fermentas) following the manufacturer’s
instructions. Quantitative RT-PCR was carried out for Col1a1,
Timp1, Tgf-b, IL-1b, TNF-a, Ccl3 and Ccl5 with Assays on Demand
obtained from http://www.appliedbiosystems.com.
Splenocyte isolation and preparation of conditioned
media
Splenocytes from CCl4 alone or CCl4 plus [
44AANA
47]-CCL5
treated WT mice (see above) were isolated using standard
protocols. Cells were cultured for 24 hours in RPMI-1640
medium (PAA Laboratories) and transferred to another tissue
culture flask. The cell concentration was adjusted to 8610
5 cells
per ml. For conditioned media, splenocyte suspensions were
incubated for 48 hours with 10 mg/ml Concanavalin A (Sigma-
Aldrich). The supernatant was centrifuged for 10 min at 9006gt o
remove cells and debris.
Cell migration assay
A cell migration assay was performed using a modified Boyden
Chamber. The stellate cell line GRX [18][9] (2.5610
5 cells/ml)
was placed in the upper chamber in RPMI-1640 medium with
10% fetal calf serum (FCS) and exposed to conditioned media of
splenocytes isolated from CCl4 or CCl4 plus [
44AANA
47]-CCL5
treated WT mice in the lower chamber. After 4 hours of
incubation at 37uC, cells that migrated to the lower chamber
were counted in 6 randomly chosen (magnification, 6100) fields.
All experiments were replicated at least twice in quadruplicates.
Cell proliferation assay
GRX cells were starved for 16 hours in RPMI-1640 medium
without FCS and stimulated for 24 hours with conditioned media
from splenocytes of treated and untreated WT mice (see above). As
controls RPMI-1640 medium with 10% FCS respectively without
FCS was used. Proliferation of cells was measured by colorimetric
immunoassay (Cell Proliferation Elisa, Roche Applied Science)
following the manufacturer’s instructions.
Statistical analysis
Data are given as means 6 SEM. Continuous variables were
compared by two-sided t-tests with Welch’s correction in case of
unequal variances. P-values less than 0.05 were considered
significant in all analyses. Statistical tests were performed by
GraphPad Prism 5.
Results
[
44AANA
47]-CCL5 ameliorates acute liver injury through
reduced immune cell infiltration
WefirstsubjectedmicetoasingletoxicinsultwithCCl4toinduce
acuteliverinjury.Miceweretreatedwitheither[
44AANA
47]-CCL5
or vehicle to assess the effects of interfering with CCL5 oligomer-
ization and glycosaminoglycan bindingon the severity ofacute liver
damage in this model. As depicted in figure 1A, administration
[
44AANA
47]-CCL5concomitantlytoCCl4resultedinreducedALT
levels 48 h after injury compared to vehicle treated mice (P,0.01).
Interestingly, [
44AANA
47]-CCL5 did not modulate the ALT levels
at 24 h what might mirror a direct cytotoxic effect of CCl4 which is
not modifiable by immune interventions. Furthermore, it should be
noted that the ALT levels 48 h after CCl4 administration are still
much higher that the ALT levels in naı ¨ve animals. The same results
were obtained for AST levels (data not shown). Decreased
hepatocellular damage at 48 h was also reflected by a lower extend
of hepatic necrosis as assessed by histology (Fig. 1B). Since
Figure 5. Treatment with [
44AANA
47]-CCL5 leads to qualitative
changes in splenocytes. (A) Splenocytes were isolated from
[
44AANA
47]-CCL5 and vehicle treated mice and conditioned mediate
of splenocyte cultures were assessed for stellate cells migration in
a Boyden chamber. Conditioned medium of splenocytes isolated from
[
44AANA
47]-CCL5 treated mice (24 and 48 h after CCl4 application) was
significantly less effective in inducing stellate cell migration compared
to splenocytes isolated from vehicle treated mice. (B) Conditioned
medium from mice treated [
44AANA
47]-CCL5 was also less effective in
inducing stellate cell proliferation as assessed by BrdU incorporation. *
P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0036614.g005
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44AANA
47]-CCL5 is thought to mainly inhibit the recruitment of
leukocytes by reduced CCL5 binding to endothelial cells [19], we
next analyzed the overall inflammatory infiltrate in the damaged
livers. Indeed, treatment of the mice with [
44AANA
47]-CCL5
significantly reduced the overall inflammatory cell infiltration 24 h
after CCl4 administration, as assessed by FACS counting of CD45+
cells, compared to vehicle treated animals (Fig. 1C, P,0.01).
Reduced inflammatory liver damage was further evidenced by RT-
PCRsforpivotalinflammation-relatedgenesinmicewithorwithout
[
44AANA
47]-CCL5 treatment (Fig. 1D). Specifically, a significantly
reduced hepatic mRNA expression of IL-1b, Tnf-a and the
chemokine Ccl3 preceded the ameliorated ALT levels in
[
44AANA
47]-CCL5comparedtovehicletreatedmice.Interestingly,
the mRNA expression of CCL5 was not different between the two
groups, supporting that compensatory CCL5 synthesis is not
induced by [
44AANA
47]-CCL5.
Liver fibrosis is strongly reduced in [
44AANA
47]-CCL5
treated animals
After having shown that treatment with [
44AANA
47]-CCL5 has
a strong impact on the extent of acute inflammatory liver damage,
we next evaluated whether this antagonistic strategy does also
inhibit progression of liver fibrosis induced by repetitive CCl4
intoxications. As depicted in figure 2A, mice treated with
[
44AANA
47]-CCL5 indeed showed a reduced extend of scar
formation compared to vehicle treated animals. The improved
severity of fibrosis in the [
44AANA
47]-CCL5 treated animals was
quantified by a significant decrease in the Sirius red-positive area
(P,0.01, Fig. 2B) and a reduced hepatic concentration of the
collagen-specific amino acid hydroxyproline (reduction of 30.1%,
P,0.01, Fig. 2C), respectively. Although there was also a trend
towards lower ALT levels, Furthermore, the mRNA expression of
the fibrosis-associated genes Col1a1 and Timp1 was significantly
reduced in the livers of [
44AANA
47]-CCL5 compared to vehicle
treated mice (both P,0.05, Fig. 3A). In addition, the mRNA
expression of the important fibrogenic cytokine Tgf-b was reduced
by 32% in [
44AANA
47]-CCL5 treated mice compared to vehicle
treated mice, although this difference did not reach statistical
significane due to the high variation of expression within the
groups. Since Timp1 is mainly expressed by hepatic stellate cells,
we also assessed the activation status of these pivotal pro-fibrogenic
cells [20] by determination of aSMA expression. As shown in
figure 3B, treatment of mice with [
44AANA
47]-CCL5 resulted in
a reduced expression of aSMA as assessed by immunohistochem-
istry and western blot analysis of total aSMA protein in the liver.
Thus, the reduced fibrosis phenotype in [
44AANA
47]-CCL5
treated mice appeared to be associated with a strongly reduced
activation of hepatic stellate cells.
[
44AANA
47]-CCL5 leads to quantitative and qualitative
changes in the immune response following CCl4
administration
We and others have recently shown that hepatic stellate cells are
a main target of CC chemokines during liver fibrogenesis which are
mainly secreted by liver infiltrating immune cells [9,15]. Thus, we
nextanalysedwhethertreatmentwith[
44AANA
47]-CCL5alsoleads
to reduced immune cell infiltration during chronic liver injury with
CCl4. Indeed, the infiltration of CD45+ leukocytes was strongly
reduced in [
44AANA
47]-CCL5 compared to vehicle treated mice
(Fig.4,upperpanel).Sincechemokines,includingCCL5,aremainly
secreted by T-cells and monocytes/macrophages during liver
fibrogenesis [21], we specifically determined the recruitment of
thesecellsintotheliveratpeakoffibrosis.Asdepictedinfigure4,the
infiltration of both cell populations was indeed reduced in
[
44AANA
47]-CCL5 treated mice as assessed by immunohistochem-
istry for CD3 and F4/80, respectively. As CCL5 is a main
chemoattractant for both ofthese cell populations [22], theseresults
are well in line with the proposed action of [
44AANA
47]-CCL5
whichhasabrogatedglycosaminoglycanbindingandformsinactive
heterodimers with WT-CCL5 thereby inhibits transendothelial
migration of immune cells induced by CCL5.
Apart from these quantitative changes inimmunecell subsets, we
also assessed whether [
44AANA
47]-CCL5 has an impact on
qualitativeaspectsoftheimmuneresponse.Tothisend,splenocytes
of [
44AANA
47]-CCL5 or vehicle treated mice were isolated and the
direct effects of conditioned media of these cells after ConA
stimulation on hepatic stellate cells were analyzed. The results are
presented in figure 5. Compared to vehicle treated mice,
conditioned medium from [
44AANA
47]-CCL5 treated mice signif-
icantlyreducedthemigration(Fig.5A)andtheproliferation(Fig.5B)
of hepatic stellate cells in vitro. As both aspects are important
parameters of these cells during fibrogenesis [20], [
44AANA
47]-
CCL5appearstoalsoimpactthebiologyofthesecellsbymodulating
qualitative changes of the immune response outside the liver.
Discussion
The findings presented in the current study further establish an
important role of the CC chemokine CCL5 in acute and chronic
liver diseases. There is now ample evidence that this particular
chemokineand itsreceptors playafunctional roleinmurine models
of acute [23] and chronic liver diseases [9,15]. Furthermore,
expression data and genetic analysis also suggest that CCL5 is
involved in the pathogenesis of liver diseases in humans
[12,13,14,24]. Thus, CCL5 might be an attractive candidate for
antagonistic studies to inhibit the progression and/or accelerate the
regression of chronic liver diseases. Indeed, we could recently show
that administration of an amino-terminally modified CCL5
molecule (Met-CCL5 [25]), which is an antagonist of the CCL5
receptorsCCR1andCCR5,isabletoameliorateexperimentalliver
damage in mice [9]. However, this particular antagonist blocks not
onlytheactionofCCL5butalsoofotherligandsofthesechemokine
receptors, including CCL3 and CCL4, which might have
differential effects within and outside the liver [16]. We therefore
investigated another principle of interference with the chemokine
system in the current study which is not based on receptor
antagonism, and might exhibit another pattern of side effects. The
mutated chemokine [
44AANA
47]-CCL5 is known to interfere with
heparin binding and oligomerization of CCL5, which are both
important biological aspects of it’s activity in vivo [26,27]. This
antagonist has been shown to limit inflammatory cell recruitment
intotheperitonealcavity,bronchoalveolarairspaceandtheCNSin
mice, thereby ameliorating the phenotype of inflammation in these
organs [17]. Furthermore, [
44AANA
47]-CCL5 is able to ameliorate
myocardial reperfusion injury in atherosclerotic mice [19]. We here
extend these earlier findings by showing that systemic administra-
tion of [
44AANA
47]-CCL5 is also able to strongly inhibit the
infiltration of immune cells into the damaged liver. This therapeu-
tical effect was true for an acute model of liver injury as well as
achronicmodelleadingtoliverfibrosis.Asitisnowwellestablished
that infiltrating immune cells play a pivotal role in both phenotypes
of liver disease [28], these effects of [
44AANA
47]-CCL5 might be
considered as the driving force behind the observed reduction of
liver damage. Since T-cells and macrophages are known to carry
receptorsforCCL5[29],wesystematicallyaddressedtheinfiltration
of these cells into the liver by immunocytochemistry. As depicted in
figure 4, the infiltration of both of these cell populations was indeed
CCL5 Antagonism in Liver Disease
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44AANA
47]-CCL5comparedtovehicletreatedmice.As
T-cells [30] and monocytes/macrophages [31] are considered as
pivotal pro-fibrogenic cell populations, these results might largely
explain the phenotype observed in our models. In support of this
hypothesis immune cell populations which do not carry CCL5
receptors (e.g. B-cells) were not changed by treatment with
[
44AANA
47]-CCL5 (data not shown). In the acute model of liver
injury the reduced infiltration of immune cells was associated with
a strong reduction of pivotal inflammatory genes, while in the
chronic model reduced cell recruitment was linked to diminished
HSC activation. This finding further emphasizes the important
interplay between immune cells and HSCs during different types of
liver injury [32].
Nevertheless, we also observed qualitative differences of immune
mediated HSC activation in mice treated with [
44AANA
47]-CCL5.
To this end, we isolated splenocytes from mice treated with
[
44AANA
47]-CCL5 or vehicle and used the supernatant of these
culturesforassessingthemigrationandproliferationofHSCsinvitro.
Indeed, splenocyte supernatants obtained from mice treated with
[
44AANA
47]-CCL5 were significantly less potent in inducing
migration and proliferation of HSCs. Thus, the effects of
[
44AANA
47]-CCL5 in our liver disease models appears to be
mediated not only by quantitative effects of immune cell infiltration
into the liver, but also by qualitative changes outside the liver.
Whether this is due to the function of [
44AANA
47]-CCL5 to
sequester endogenous CCL5 by forming non-functional hetero-
dimers [17] needs to be analyzed in further studies. Furthermore,
other cytokines might be involved in the modulation of stellate cell
behaviour. In a first attempt to identify these cytokines, we
determined a subset of these molecules in the conditioned media
of activated splenocytes, but could not detect major differences
between cells isolated [
44AANA
47]-CCL5 and vehicle treated mice
(data not shown). Thus, the identification of the molecules involved
inthemodulationofHSCbehaviourinourmodelsisstillwarranted
but beyond the scope of the current study.
In summary, the current results suggest that interference with
oligomerization and glycosaminoglycan binding of the chemokine
CCL5 is able to ameliorate experimental liver injury and fibrosis in
vivo. Although we cannot decide from our data that this approach
is associated with fewer side effects than direct chemokine receptor
antagonism, this strategy of immune intervention might be further
evaluated as a novel option for the treatment of liver diseases.
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